As the global health burden of chronic disease increases, end-stage organ failure has become a costly and intractable problem. De novo organ creation is one of the long-term goals of the medical community.
Introduction
End-stage organ failure is one of the most devastating and costly problems facing modern medicine [1] . An ever increasing number of individuals join the organ donor register, but there is still a dearth of supply [2] . In 1989, there were 17,917 patients in the United States registered on the combined active and suspended solid organ transplant waiting lists. By 2015, this number had risen to 79,062 active patients with a further 44,334 on the temporary suspension list to total 123,396 individuals [3] . Approximately 21 patients die each day waiting for a transplant that will never happen due to the national shortage of available organs [4] . While solid organ transplantation has been in place for over half a century, the fortunate recipients are relegated to lifelong immune suppression with the associated increased morbidity and mortality.
The gold-standard solution of "off-the-shelf" organs that are non-immunogenic and have the viability of the host has yet to be achieved. Tissue engineering has long been a much-heralded tool that could, in theory, provide organs for those unable to receive conventional allotransplants.
Tissue engineering was pioneered in 1933 when Bisceglie [5] first demonstrated that mouse tumour cells, when encased in a polymer in the abdominal cavity of the pig, did not mount an immune response. When
Macchiarini and colleagues performed proof-of-principle studies in pigs, the prospect of human organ tissue engineering trials resurfaced [6] . Pioneered in the airway with tracheal transplantation, studies have progressed to investigate tissue-engineered transplants in humans involving the nose, genital tract small bowel, lung, urethra and liver, among others [7] [8] [9] [10] [11] [12] [13] . These tissue engineered constructs may comprise scaffolds only, cells only, or both combinations of scaffolds and cells. Scaffolds may be allogenic, xenogenic, or synthetic in origin and can be seeded with autologous cells. The nascent days of this technology have been challenging but also rewarding.
All of the patients that have undergone these procedures have received transplants on compassionate grounds as a palliative measure in an attempt to extend or significantly improve quality of life (Table 1 ). In light of the published case trials on the background of the publication of a five-year follow-up to the first tissue engineered transplant, we have reached a turning point for tissue engineering organs [14] . Grafts are generally safe and well tolerated, but their utility has yet to be demonstrated on a larger scale. The first clinical trial of this technique is due to begin in 2015 (RegenVox study).
Nevertheless, the early studies reveal host immune response to the graft has profound effects on the viability and durability of the graft. Grafts may be immunogenic (capable of triggering an immune response), antigenic (capable of binding and interacting with the host but not necessarily causing an immune response), or both. How immunogenic a graft is depends on a variety of factors including graft complexity, insolubility, and protein content. Furthermore, the "dose" of the graft, how many grafts are required, the route in which the graft is delivered, the location of the graft, and any knock on treatment that is required all affect the extent and type of immune response that occurs. Finally, the immune response is not all deleterious; immune modulation and graft remodelling may be valuable tools for improving graft The purpose of this review is to discuss the role of the host immune system in confounding or promoting the advancement of organ tissue engineering and the areas of research that are promising. Figure 1 demonstrates the current possibilities for skeletal muscle reconstruction alone.
Although the choice of biomaterials has been reviewed elsewhere [37] , here we provide an overview of the immunological profile of the biomaterials used in scaffolds ( Table 2 ). 
Synthetic biomaterials
Synthetic biomaterials are widely available and already have many uses within medicine. Examples include hydrogel, plastic, polystyrene, and gold [39] . The advantages of synthetic materials are clear: they are largely inert, mass producible, and can be tailored to meet the specific requirements of the organ in question. Their hydrolytic properties mean that even their degradation profile can be controlled and manipulated [40] . Unfortunately, synthetic biomaterials are among the most immunogenic biomaterials, strongly activating the innate immune system. Recent research has demonstrated that, through their effects on toll like receptors, synthetics trigger pathogen associated molecular proteins and local inflammasomes, causing widespread damage at the graft site [41] . One potential tool to circumvent the immune profile of synthetics is to use peptides or other biologicals to coat the surface of synthetic biomaterials [42] . An even more sophisticated approach would be to coat a synthetic material with a modulatory extracellular matrix in order to modulate the host response [41] .
Biological de novo biomaterials
Biological biomaterials that can be constructed de novo into scaffolds include collagen [42] , fibrinogen, hyaluronic acid, GAGs, hydroxyapatite, chitosan, silk [43] and starch [44] . De novo biological materials are promising because they are readily available, cost-effective, and able to be produced in large numbers.
Concerns include their intrinsic biophysical properties (tensile strength, contractility, etc), degradation profiles, sterilisation cost, and pathogenic potential. Studies of starch-based scaffolds implanted subcutaneously and intramuscularly suggest good integration of the materials in the host independent of the tissue location [44] . Silk-based biomaterials provoke an untransformed CD14+ human monocyte response characterized by IL-1β (an inflammatory cytokine) and IL-6 (an acute phase reactant) but not IL-10 (antiinflammatory) gene expression and protein production [43] . The macrophage response to silk is mostly mediated by the sericin protein [45] . Large silk biomaterials fail to induce peripheral T cell activation, an interesting finding that merits further study. Current hypotheses include a role for expression markers that down-regulate T cell responsiveness [43] . Silk could therefore find several implementations: as a surgical device to replace conventional mesh, as a cloak for other biomaterials, or as a research device for further elucidating T cell downregulation.
Xenogenic biomaterials
An ideal biomaterial would have adequate biomechanical properties, be readily available, promote a favourable immune response, and present a low risk for infectious disease transmission [22] . The use of xenogenic material is therefore particularly suitable. However, the immunogenicity of xenogenic biomaterials is still the primary drawback to their use. Heart valves, the ubiquitous usage of a xenogenic biomaterial, are still subject to immune mediated degradation in an area that has a minimal immune response [46] .
The Gal epitope has been the most studied in this context. For example, pig to primate liver transplantation with livers transgenic for human CD55 (which mediates complement activation) or α-1,3-galactosyltransferase knockout was associated with extended survival [47, 48] . Although modifying the Gal epitope may mitigate acute rejection, there is still a delayed form of antibodymediated rejection. There are most likely to be non-Gal based xenoantigens, although these have yet to be fully identified [49, 50] . Ideally, a xenogenic scaffold could be decellularized and modified to the point where acute and chronic rejection were minimized.
One potential route to the use of xenogenic biomaterial is through 
Decellularisation and immunogenicity
Allogenic biomaterials are those derived from another host that have been modified in order to function as a graft. Allogenic materials are advantageous because they maintain tissue composition and architecture and are very similar to the native tissues they aim to replace. Hypothetically, allogenic materials can be harnessed to both remodel and regenerate a host tissue while circumventing the immune response [57, 58] . Considerable research has focused on creating non-immunogenic allogenic materials. One of the first steps in "treating" an allogenic biomaterial is to decellularize the graft. The ultimate aim of decellularisation techniques is the removal of antigens that elicit an adverse immune response while preserving scaffold (i.e., ECM)
integrity. This integrity is typically measured through collagen, elastin, sglycosaminoglycan, and growth factor content, as well as structural and ultrastructural integrity. Cryofixation with glutaraldehyde and preservation and fixation [30] been attempted but generated non-viable grafts.
One early method, pioneered by Yates et al, removes 98.2% of nucleated cells and 98.7% of soluble protein in bone via wash and centrifugation steps [59] . Decellularisation methods have developed since then with a wide variety of results both in terms of functionality and structural content [60] [61] [62] . It is important to note that the two do not entirely correlate [63] . However, in a recent study, rabbit cricoarytenoid dorsalis muscles were harvested and analysed using different methods: histochemical, immunohistochemical, and molecular. Latrunculin B, potassium iodide, potassium chloride, and deoxyribonuclease all led to total DNA clearance, decreased MHC II expression, and preservation of structural integrity [57] . may still be present after decellularization. These DAMPs are not only found in the native tissue but they are also actively secreted during cell necrosis and by macrophages that respond to the acute tissue injury. DAMPs upregulate HMGB1, which mediates the proinflammatory response through increased chemokine and TLR4 mRNA expression [66] . Counterintuitively, minimizing this initial macrophage response by inhibiting a well-characterized DAMP, HMGB1, led to an increase in the proinflammatory response, cell death, and chemokine expression [66] . There is therefore a potential for DAMPs to be manipulated as bioinductive molecules within an ECM scaffold.
Decellularization also does not, however, fully remove MHC I and II [67] .
Interestingly, Haykal et al noted that decellularization delays leukocyte involvement but leads to cartilage degradation [67] . Macrophages are very plastic and can switch from M1 to M2 in response to the environment [68, 69] .
In theory, the injury caused by inserting a decellularized scaffold can modulate the macrophage response to an immunotolerant, injury response M2 macrophage type [70, 71] (See Section 4.1). Macrophage repolarization could lead to site-appropriate remodelling [72, 73] , and is therefore a valuable direction of future study.
The immune response to decellularised scaffolds has raised questions and offered solutions for harnessing the immune response to scaffolds (See Section 4.1). Recellularising grafts with autologous cells alters the immune response to these grafts (See Section 2.2).
Recellularisation and immunogenicity
Once scaffolds have been decellularized, recellularization with appropriate cells is the ultimate goal. Which cells to use and when to use them are questions that have been addressed elsewhere [74] . Recently, one group has grown three individual scaffolds: the epithelial (physical barrier), fibroblast (ECM production), and dendritic cell (immune sensing) layers. The epithelial layer in particular was grown at the air-liquid interface for four weeks leading to a functional barrier and transepithelial electrical resistance mediated by tight junctions [75] . As regards the immune response towards these new cells, cellularization provides an important opportunity to modulate the immune response.
Stem cells can be loaded with the required genes prior to incubation. For example, Holladay et al found that, when stem cells were transfected with IL-10 before being loaded onto a collagen scaffold, there was a significant improvement in the survival of the cells [76] . Such techniques should be approached with caution. For example, although some factors, such as FGF, activate the key regenerative processes of inflammation, wound response, and chemotaxis, they also provoke a strong immune response [77] .
Incorporating the use of external factors in promoting cellularization and graft survival is still in its nascent stages. In one of the human cases, a 12-year old boy with congenital tracheal stenosis was transplanted with a scaffold seeded with bone marrow mesenchymal stem cells and granulocyte-colony stimulating factor with recombinant erythropoietin and transforming growth factor beta applied. A subsequent strong neutrophil response at 8 weeks generated neutrophil extracellular traps, which considerably affected mucosal clearance [19] . Therefore, current efforts focus on the use of autologous cells rather than stem cells.
Using autologous cells prior to implantation initially requires a bioreactor.
Ideally, the bioreactor presents a similar environment to the host optimal for cell growth and integration [41] . For example, lymph nodes have been assessed in mice as scaffolds. The lymph nodes were processed using sodium dodecyl sulfate detergent, and the matrices were repopulated with splenocytes, implanted in submuscular pockets in the host, and harvested 14 days later. They were then implanted in the renal capsule of syngenic or allogenic mice recipients and analysed. The result was successful in vivo cell delivery with no significant antigenic response [78] . The greatest concern with the applicability of such a method is that the renal capsule itself is a privileged site that induces tolerance [79] . A further concern with such a method is the need to house the tissue in a bioreactor as, when tried in a human patient without use of a bioreactor, the graft did not have biomechanical strength until 18 months [80] .
A human study of allogenic trachea tissue engineering used the patient's forearm as a bioreactor [81] . The authors have subsequently employed this method in five patients with similar results in four of them: with withdrawal of immunosuppression, the patients tolerated the grafts well [18] . In one patient however, the graft was not immune tolerant at withdrawal of immunosuppression. The host immune response led to the appropriate resoprtion of the donor mucosa. However, the donor cartilage was afforded considerable immunoprotection only by the immunosuppression [82] . The requirement for immunosuppression would be largely unsuitable for the transplant and neonatal populations. For the moment, using the host is not a feasible option for an immunosuppression-free graft but provide a potential and viable alternative for the future.
External bioreactors are currently the preferred option for growing autologous cells as they remove the potential for host morbidity and could, in theory, be made rapid and cost-effective. Bioreactors do have to, however, provide an environment that improves mass transfer, allows perfusion of vascular structures, and provides biocompartmentation as needed [83, 84] . The development of the rotating bed bioreactor leads to high rates of mass transfer and improved oxygenation of the tissue due to the shear stress [85, 86] . Simultaneous transmural and axial flow within the material increases both the mechanical strength of the scaffold and the vascular development of the seeded cells [87, 88] . In theory, cell culture in the bioreactor and inclusion of factors could minimize the immune response and maximise viability of the graft due to the greater theoretical control afforded by an extrinsic method.
Autologous cells could in theory also be grown to the scale required for whole organ engineering.
Immunological outcomes for tissue engineered organs

Lessons from case studies
Functional organ replacement is the ultimate aim of tissue engineering. Tissue engineering to date has seen major successes in using scaffolds alone or scaffolds plus cells to reconstruct body tissues. Functional organ replacement is a future endeavour, but one that is no longer enshrined in mythology [89] .
Successful attempts to create in vitro organ models include the production of the heart [90] , liver [91, 92] , lung [93] , and recently the kidney [94] . However, the patient developed stenosis in the native trachea close to the proximal anastomotic site. Certainly, identifying ways to minimize scarring given the local immune response to the changing environment is an important avenue of research [14] . These results are not reproducible: in another trial in which a 76 year old patient with non-resectable tracheal stenosis was given a tissue-engineered transplant [20] . The patient passed away shortly thereafter from a cardiac arrest secondary to severe stenosis of the coronary arteries.
However, at autopsy, the anastomoses were intact, the submucosa had reformed, there was one layer of squamous epithelium, neovascularization was occurring (lumina of capillaries and red platelets were visible), and the seeded chondrocytes were intact.
Xenogenic human case studies have also been performed. Vaginal organs were engineered using allogenic cells and xenogenic scaffolds. In these patients, the scaffolds were derived from decellularized porcine small intestine submucosa. However, the patients' own epithelial and muscle cells were cultured, expanded, and seeded onto these biomaterials. At yearly biopsy, the vaginal structure comprised three layers: epithelium, matrix, and muscle.
Furthermore, the patients reported improved sexual function. No significant detrimental immune response was recorded [8] . Xenogenic materials, such as used in this study, may prove advantageous as they are more readily producible and when "cloaked" with autologous cells, appear to be afforded some immunoprotection.
The concept of immunocloaking is also being explored in developing functional pancreatic islet cells for the treatment-resistant Diabetes [96, 97] .
An initial investigation into islet cell transplantation provided reproducible success in the short-term [98] . However, long-term insulin independence has not been achieved [99] . Several solutions have been suggested including the inclusion of laminin and collagen IV, microencapsulation, and immunocloaking.
Conrad et al bioengineered a scaffold based on decellularized pancreas extracellular matrix and mesenchymal stem cell / islet cell co-culture, generating functional endocrine tissue and reversing the diabetic state [89, 100] . Therefore, protecting the graft from the host immune response is a key predictor of success in case trials.
Creating blood vessels is vital not only for cardiovascular uses but also to develop a blood supply for more complicated grafts at other sites. The growth of blood vessels using bio-engineered scaffolds is progressing. Olaussen et al were able to transplant the first tissue engineered allogenic vessels into two pediatric patients. These grafts did not have any antibodies to Major Histocompatibility Complex I or II at follow up and remained patent with good response to pressure [24] . Acellular heart cadaveric extracellular matrix has been assessed in mice, but leads to clots even when transplanted with anticoagulation. By relining vascular conduits with rat aortic endothelial cells, a less thrombogenic left ventricle with better contractility was created. The trial arms that involved recellularizing the brachiocephalic artery and the inferior vena cava and the brachiocephalic artery led to improved rat aortic endothelial cell proliferation and von Willebrand Factor and nitric oxide synthase expression. The expression of these factors decreased thrombogenicity, thereby improving graft outcome [101] . Further rat models have also managed to reseed decellularized rat hearts with cardiac endothelial cells. By 8 days post-seeding, under physiological load, the hearts could generate pump function equivalent to 2% of adult function in a modified working heart preparation [90] . These studies suggest the potential for functional myocardial tissue replacement. However, the need for additional factors raises questions about how such factors could be incorporated as these factors are, in themselves, immunogenic.
An observational first-in-human trial of five patients demonstrated the efficacy of engineered autologous tissue grafts for nasal reconstruction following tumour resection. The selected patients possessed a greater than 50% alar subunit defect after non-melanoma excision on the alar lobule. The procedure for cellularisation of the graft involved expanding, seeding, and culturing autologous chondrocytes in serum onto collagen type I and II over four weeks.
These grafts were remodelled into fibromuscular fatty structures similar to the tissue at the site of implantation. There were no adverse events reported following implantation and patient satisfaction was high at 1 year. However, no cartilage was present at 6 months. In goats, however, engineered nasal cartilage grafts implanted in the knee remain cartilaginous. What factors, if any, are necessary to maintain and develop these grafts are still unknown [13] .
It may not even be necessary to maintain the cartilaginous graft if the remodelling into the scar provides the necessary properties as in this case.
Innate immune response to biological scaffolds
Even as trials are providing insight as to what is occurring macroscopically, there is a growing body of evidence to suggest that the innate and adaptive immune response can both promote and undermine the viability of these grafts. The innate immune response to biological scaffolds can lead to early failure of the graft but, even in the absence of early graft failure, may also have knock-on effects for graft function and viability long term. The initial injury of placing the graft provokes an inflammatory response. The terminal biochemistry of the graft surface then modulates the serum proteins that adsorb to it. Biomaterial adherent macrophage apoptosis is also increased by hydrophilic substrates in vivo. Hydrophilic substrates also decrease monocyte and macrophage adhesion and fusion used in an in vivo rate cage implant system [102] . For example, integrins bind less if the molecule is hydrophilic and anionic [41] . Passive modulation of the biomaterial surface properties may limit macrophage adhesion, activation, and fusion to foreign body giant cells [41] .
Promotion of a long-term constructive macrophage phenotype is vital in achieving graft tolerance [103] . The classical macrophage type, M1, is IL- PPARγ signalling predominated in the polarization of macrophages from M1 (CD80+) towards M2 (CD163+) [105] . One of the problems with the use of a porcine model is that there is a dearth of markers for porcine cells. Another study in mammalian ECM found that degradation from ECM bioscaffolds promotes M2 macrophage polarization in vitro leading to the migration and myogensis of smooth muscle progenitors from solubilized small intestine submucosa. The secretome of this constructive graft was similar to that of IL-4 polarized M2 macrophages [106] .
Adaptive immune response to biological scaffolds
Proof of principle studies in humans have already demonstrated that the humoral immune response does not destroy tissue-engineered biological scaffolds. However, there may still be a cellular immune response. Indeed, the Th1 response is associated with classical acute graft rejection [73, 107, 108] . Ideally, a scaffold should have delayed degradation time, decreased sensitized T cell proliferation, and improved survival of donor-derived cells [58] . Measuring the survival and functionality of the graft in vivo is difficult. In vitro studies have demonstrated that graft survival is associated with decreased IL-2, IFNγ and increased IL-10 levels, Furthermore, in tolerant grafts, the factors IL-4, TLR2, an TLR4 and their gene expression have decreased inversely proportional to recellularization of grafts while TGF-B1 is proportional [109] . Although being able to analyse the graft is important, the real question is how to modulate the T cell response away from Th1 effector function and towards a Th2 tolerant phenotype by harnessing the macrophage M2 phenotype [69] .
Transplant studies offer valuable insight into the adaptive immune response to grafts. Transplant recipients must take immunosuppression drugs, which contribute to graft failure and are toxic to the host. Ever since [110] demonstrated that there was specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporins, researchers have been trying to come up with a way to conduct transplants without immunosuppression. Central tolerance is achieved by depleting reactive T cells in the thymus. In utero transplantation and non-myeloablative bone marrow transplantation leading to mixed chimerism have both been attempted in order to induce central tolerance [111, 112] . The latter has been demonstrated in a proof of principle study [111] . As regards peripheral tolerance, strategies have included co-stimulatory blockade by manipulating regulatory T cells or through tolerogenic dendritic cells [113, 114] .
In vitro studies have shown that decellularized scaffolds can circumvent the cell-mediated immune response and modulate this host response towards a favourable phenotype [57, 58, 115, 116] . The ONE study is currently assessing the roles of Treg cells, regulatory macrophages, and tolerogenic dendritic cells in redirecting the host response towards an M2 macrophage and Th2 lymphocyte phenotype in human transplantation [117] [118] [119] . This study will have profound implications for how immune tolerance to biological scaffolds is established and promoted especially in future trials [120] .
Immune response to biomaterials in pediatric patients
Pediatric patients represent an important population. Structural abnormalities in children that cause debilitating or life-threatening outcomes require surgery.
Pediatric patients have different requirements to adults: surgery should preferably be one time only and any resulting graft should in theory survive the length of the adult lifespan. 3% of newborns have congenital malformations including 2% with bronchopulmonary problems and tracheal problems (including agenesis, tracheomalacia, and bronchomalacia) [121] .
Congenital anomalies further affect the heart with 10,000 children requiring surgery each year. Finally, genitourinary tract problems affect 4% of livebirths, with gynaecological problems in particular [122, 123] . There are differences in the immune profile of children that have implications on the design and implementation of tissue engineered organs. A recent five-year follow-up of a tissue-engineered trachea transplanted into a 10-year old child using a decellularized autologous graft with allogenic cells has confirmed that the scaffold demonstrated long-term viability. However, there were initial interventions, and a method to achieve this replacement with lower morbidity and cost is warranted [124] .
Profile of pediatric innate and adaptive immunity
In the newborn, innate immune cells mount a different cytokine response to pathogens as compared to adults. IL-12, IFN1, and IFNγ decrease whereas IL-1β, IL-6, IL-23, and IL-10 increase [125] . Innate immunity of the newborn is polarized towards a high ratio of IL-6/TNFα production [126] . Serum collected from the newborn has increased IL-6/TNFα ratios as compared to cord blood.
The cause of the hyperactive innate immune response may be due to negative regulation of the adaptive arm via IL-10. Type I IFNs feedback on IL-10 production as well as regulation IL-1β pro-inflammation by counterregulating the IL-1R antagonist. IL-6 production is then due to both neonatal cellular (monocyte) and humoral (serum) factors. This production is then associated with elevations of IL-6 inducible reactants CRP and LPS-binding protein. [127] . An observational study of pre-term infants who developed sepsis noted that these infants had decreased monocyte class II antigen, again suggesting that the adaptive immune system is delayed [128] . This has led to the hypothesis that there is a later set point for coupling adaptive and innate immunity [128] [129] [130] . Physiologically this is logical: fetal T cells are highly responsive in cell culture to in vitro antigen stimulation, however, there are limited numbers of T cells as the newborn immune system must tolerate the mother's for birth. Minimizing or modulating the innate immune response, particularly to synthetic biomaterials, will be important in ensuring graft survival in pediatric patients.
Many in vivo and in vitro studies to date have described the deficiencies or immune deviation among T cells, B cells, and APCs in neonates [131] . There is limited IL-2 production and deficient proliferation by human neonatal T cells. suggesting that tolerance was easier to achieve [136] . How the immune profile of a pediatric or neonatal patient will present towards a tissueengineered biomaterial is unclear. However, the upregulation of the innate immune response and downregulation of the adaptive suggests that initial immunoprotection say through cloaking could be particularly valuable as subsequent degradation would be more likely to produce a tolerogenic graft.
Cell replacement and immune desensitisation
Cell replacement following immune desensitisation has been proposed as a therapy for CNS diseases, particularly in neonates. The immune response mounted against stem cells often hampers in vivo investigations. Current research has recognised the need for immune modulation in order to carry out these transplantations in animal models [137] . Two recent reports have demonstrated conflicting results with neonatal tolerance to xenografts in rats.
The first found that human embryonic stem cell-derived mesenchymal stem cells survived as long as eight weeks and with a dampened CD4+ inflammatory response when the rats were immune desensitised prior to the transplantation [138] . The conflicting study employed the same method but used human glial-restricted precursor cells from the foetus [139] . A third study demonstrated that the method was reproducible using the same embryonic stem cell-derived mesenchymal stem cells as the first study in rat joint cartilage [140] . However, when reproduced in three strains of neonatal immune-intact mice, using two different brain transplant regimes and three independent stem cell types, implanted cells were rapidly rejected [141] . The efficacy of immune desensitisation has yet to be fully determined, however this is still a promising technique for avoiding some of the cell-related immune response.
Lessons from organ transplantation in pediatrics
Tolerant pediatric transplants have unique T and B cell profiles. CD4+CD25+
Treg cells have been implicated in the development of neonatal tolerance to transplantation antigens [131] . In a mouse model, CD4+CD25+ shown that, with a high dose of T cell-depleted haematopoietic progenitor cells, no suppression is required to control graft rejection or graft versus host disease [144] . The event free survival is similar but there are important implications of immunodepletion. There may be delayed immune reconstitution, viral reactivation and other infectious complications, decreased graft versus leukaemia effect, an increased incidence of graft failure, and increased risk of Epstein Barr Virus associated lympho-proliferative disorder.
Immunodepletion also reveals how T cell tolerance may occur. T cell receptor Vδ2 γδ T cells are implicated in host defence whereas Vδ1 γδ T cells have a role in modulating the immune response [145, 146] . Studies have role for γδ T cell reconstitution in improving event-free survival. For example, infection increases in the presence of low numbers of Vδ2 γδ T cells. There is also a significant impact of the maximum number of CD3+, CD4+, and CD8+ T cells and donor source on the Vδ2 γδ T cell recovery [147] . When Vδ1/Vδ2 ratio was assessed in a liver transplant cohort, it was found that, when the ratio was the highest, patients were more likely to be graft tolerant. Furthermore, the Vδ1 gene had a complementarity-determining region 3 sequence (100% homologous) among all tolerant patients and dominant in 6 out of 9 patients.
This clone was also found in some of the normal livers but none of the rejected organs [148] . Grafts could in theory be modified or selected for favourable T cell phenotype. One could imagine a bioreactor in which the host immune response was mimicked and the graft manipulated using genetic and environmental means to promote a tolerant response.
Conclusions
Organ tissue engineering is still in its earlier days, but the questions have now changed from whether or not it is possible, to how to fully harness its potential.
One of the greatest stumbling blocks to the use of xenogenic, allogenic, synthetic or de novo biological tissues is the continued ability of the graft to provoke an immune response in the host. The immunogenicity of grafts has implications both for the scale of production that may be achieved and also for the outcomes of grafts once transplanted into the host. Additionally, the pediatric population has a robust innate immune system but a fledgling adaptive immune response, which could present significant problems with the initial scarring and graft remodelling. One solution to solving the immune problem is to effectively cloak grafts in immune-neutral substances such as the extracellular matrix or peptides. Additionally, studies are finding techniques to suppress or harness the immune system to promote graft tolerance. Through the ONE study as well as further investigation into macrophage and T cell class switching, harnessing the immune response could overcome the major immunological barriers to whole organ tissue engineering. The questions (and beginnings of answers) presented here will continue to provide challenging questions for clinicians and researchers looking to implement and advance tissue engineering.
